Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FGR | P09769 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24421365 | 0.81 | DPP4 (0.51) | DPP4MPOKMT2AMEN1ALDH1A1 | |
| SCHEMBL7568712 | 0.79 | DDB1 (0.43) | HSPA1APABPC1DPP4MPOKMT2A | |
| SCHEMBL9450349 | 0.79 | KDM4E (0.43) | HSPA1APABPC1ADORA2AMPOKDM4E | |
| SCHEMBL11214758 | 0.77 | HSPA1A (0.55) | HSPA1APABPC1DPP4ADORA2APTPRC | |
| SCHEMBL2036747 | 0.77 | MEN1 (0.58) | HSPA1APABPC1DPP4ADORA2APTPRC | |
| SCHEMBL43760 | 0.77 | PABPC1 (0.55) | HSPA1APABPC1DPP4ADORA2APTPRC | |
| SCHEMBL626365 | 0.76 | MPO (0.48) | PTPRCMPOKDM4EKMT2AMEN1 | |
| SCHEMBL29448054 | 0.76 | MPO (0.48) | PTPRCMPOKDM4EKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL10728562 | 0.74 | MPO (0.47) | PTPRCMPOKDM4EKMT2AMEN1 | |
| SCHEMBL19370912 | 0.74 | HSPA1A (0.51) | HSPA1APABPC1DPP4ADORA2APTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271901-A | Alcohol-soluble environment-friendly printing ink and preparation method thereof | 厦门欧化实业有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-2373329-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | The Regents of the University of California (US) | 2011-10-12 | — | — | EP | claimed |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-29 | — | — | US | claimed |
| WO-2010123527-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | claimed |
| WO-1997043643-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA INDUCED MUCIN PRODUCTION: COMPOSITIONS AND TREATMENTS FOR CYSTIC FIBROSIS PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-11-20 | — | — | WO | claimed |
| JP-5163240-A | — | — | None | — | — | JP | disclosed |
| CN-118271901-A | Alcohol-soluble environment-friendly printing ink and preparation method thereof | 厦门欧化实业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-2066673-B1 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE CORP (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-102036990-B | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-1102643-A | Substituted derivatives of diaminophthalimide | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | CN | disclosed |
| CN-1102643-A | Substituted derivatives of diaminophthalimide | CIBA GEIGY AG (CH) | 1995-05-17 | — | — | CN | disclosed |
| EP-0516588-B1 | Substituted diaminophtalimides and analogues | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
| EP-0600830-A1 | Substituted derivatives of diaminophthalimide as protein-tyrosine kinase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| JP-H05163240-A | SUBSTITUTED DIAMINOPHTHALIMIDE AND ANALOGUE | CIBA GEIGY AG | 1993-06-29 | — | — | JP | disclosed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | disclosed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | disclosed |
| EP-0516588-A1 | Substituted diaminophtalimides and analogues | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | EGFR, HDGF, HGF | HSPA1A 1233/4885PABPC1 2148/4885DPP4 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.